ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 0289 • ACR Convergence 2022

    Real-world Data of Tofacitinib versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients with Rheumatoid Arthritis from a Drug-based Registry

    Song-Chou Hsieh1, Wei-Sheng Chen2, Jui-Chieh Hu3, Wan-Yu Sung4, Wen-Chan Tsai4, Hsiang-Cheng Chen5, Chung-Ming Huang6, Edward Kuo7, James Wee8, John Woolcott9 and Yi-Hsing Chen10, 1Division of Rheumatology, Immunology and Allergy, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 2Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 4Department of Allergy, Immunology, and Rheumatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Division of Immunology, Rheumatology, and Allergy, Department of Medicine, Tri-Service General Hospital, Taipei, Taiwan, 6Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 7Pfizer Ltd, Taipei, Taiwan, 8Pfizer Inc, Makati City, Philippines, 9Pfizer, Inc, Collegeville, PA, 10Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and was approved under Taiwan's National Health Insurance (NHI) reimbursement system in…
  • Abstract Number: 0809 • ACR Convergence 2022

    Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02

    Kathleen Richter1, Halimuniyazi Haliduola1, Jana Schockaert2, Aurélie Mazy3, Nataliya Reznichenko4, Eric Guenzi5 and Fausto Berti6, 1Alvotech, Jülich, Germany, 2ImmunXpert, Ghent, Belgium, 3ImmunXpert, Charleroi, Belgium, 4Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Southern Region, Zaporizhzhia, Ukraine, 5UGA Biopharma, Bonn, Germany, 6Alvotech, Zürich, Switzerland

    Background/Purpose: A common reason for clinical development failure of biologic medicines is immunogenicity. Immunogenicity is traditionally measured by detecting neutralizing (NAb) anti-drug antibodies (ADA) in…
  • Abstract Number: 1614 • ACR Convergence 2022

    Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study

    Denis Poddubnyy1, Joachim Sieper2, Servet Akar3, Santiago Muñoz-Fernández4, Hildrun Haibel2, Torsten Diekhoff5, Mikhail Protopopov6, Elisabeth Altmaier7, Fabiana Ganz8 and Robert Inman9, 1Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Charité - Universitätsmedizin, Berlin, Berlin, Germany, 3Izmir Katip Celebi University School of Medicine, Izmir, Turkey, 4Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, 5Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, 6Charité Universitätsmedizin Berlin, Berlin, Germany, 7GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, 8AbbVie, Inc., Luzern, Switzerland, 9University Health Network, Toronto, ON, Canada

    Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
  • Abstract Number: 2273 • ACR Convergence 2022

    Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study

    Amy Mudano1, Gary Cutter2, Ted Mikuls3, Geoffrey Thiele4, Mark Law4, Bart Hamilton4, Michael Zikry5, Kelly Y. Chun6, Monique Bastidas7, Michael George8, Lisa Williams9, Kevin Winthrop10, Mark Busch11, Stanley Cohen12, Roman Czubatyj13, Rajesh Kataria14, Reshma Khan15, Soha Mousa16, Jose Pando17, Elizabeth Perkins18, Shanmugapriya Reddy19, Delfin Santos20, Joy Schechtman21, Frank Scott22, Sucharitha Shanmugam23, Atul Singhal24, John Tesser25, John Tower26, Swamy Venuturupalli27, Sean Joseph Wollaston28, Conrad Ziembinski29 and Jeffrey Curtis30, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5LabCorp, Burlington, NC, 6Labcorp, Calabasas, CA, 7LabCorp, Northridge, CA, 8University of Pennsylvania, Philadelphia, PA, 9Illumination Heath, Hoover, AL, 10Oregon Health & Science University, Portland, OR, 11Family Arthritis Center-Jupiter, Jupiter, FL, 12Metroplex Clinical Research Center, Pittsburgh, PA, 13Arthritis Physicians LLC, Rochester Hills, MI, 14Southern Ohio, Wheelersburg, OH, 15Palm Beach Rheumatology and Wellness, Jupiter, FL, 16Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, 17Rheumatology Consultants of DE, Lewes, DE, 18Rheumatology Care Center, Hoover, AL, 19Southwest Florida Rheumatology, Riverview, FL, 20Rochester Rheumatology, Rochester Hills, MI, 21SunValley Arthritis Center, Peoria, AZ, 22Arthritis Medical Center, Arroyo Grande, CA, 23Rheumatology and Arthritis Care Center, Exton, PA, 24Southwest Rheumatology Research, Mesquite, TX, 25Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 26Arthritis Physicians LLC, Rochester, MI, 27Cedars-Sinai Medical Center, Los Angeles, CA, 28Rheumatology Associates, North Hollywood, CA, 29CZ Rheumatology, Coral Springs, FL, 30Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
  • Abstract Number: 0297 • ACR Convergence 2022

    Effect of Upadacitinib, Adalimumab, and Placebo on Residual Pain Among Patients with Rheumatoid Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

    Louis Bessette1, Adriana Kakehasi2, Neil Basu3, David A. Walsh4, Andra Balanescu5, Clifton Bingham6, Andrew Garrison7, Ivan Lagunes8, sander strengholt9, Ralph Lippe10 and Maxime Dougados11, 1Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 2Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, 3University of Glasgow, Glasgow, Scotland, United Kingdom, 4University of Nottingham, Nottingham, United Kingdom, 5University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, 6Johns Hopkins University, Baltimore, MD, 7AbbVie, Inc., North Chicago, IL, 8AbbVie, Inc., Mettawa, IL, 9AbbVie, Inc., Abcoude, Netherlands, 10AbbVie, Inc, Wiesbaden, Germany, 11Université de Paris, Paris, France

    Background/Purpose: Residual pain remains a challenge that prevents patients (pts) with RA from achieving a better quality of life. Current RA treatments have demonstrated efficacy…
  • Abstract Number: 0866 • ACR Convergence 2022

    Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV) Treated with Methotrexate and Infliximab

    Sheila Angeles-Han1, Grant Schulert1, Megan Quinlan-Waters1, Alexandra Duell1, Jennifer Huggins1, Tiffany Nguyen2, Cameron Sapp2, Sumit Sharma3, Sunil Srivastava4 and Arjun Sood2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Eye Institute, Cincinnati, OH, 3Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 4Cole Eye Institute, Cleveland Clinic, Cincinnati, OH

    Background/Purpose: Pediatric uveitis is commonly associated with rheumatic disease and can lead to sight-threatening complications. Initial treatment are glucocorticoids and subsequently methotrexate (MTX) and TNF…
  • Abstract Number: 1669 • ACR Convergence 2022

    Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis

    Anne Bass1, Noha Abdel-Wahab2, Pankti Reid3, Jeffrey Sparks4, Cassandra Calabrese5, Deanna Jannat-Khah, DrPH, MSPH6, Diviya Rajesh6, Nilasha Ghosh6, Komal Mushtaq7, Farah Al Haj8, Adewunmi Falohun9, Lydia Gedmintas10, Lindsey MacFarlane11, Senada Arabelovic11, Adi Diab2, Ami Shah12, Clifton O. Bingham III13, Karmela Kim Chan6 and Laura C. Cappelli14, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2UT MD Anderson Cancer Center, Houston, TX, 3University of Chicago Medical Center, Chicago, IL, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Cleveland Clinic Foundation, Cleveland Heights, OH, 6Hospital for Special Surgery, New York, NY, 7Cleveland Clinic, Cleveland, OH, 8Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, 9MD Anderson Cancer Center, Houston, TX, 10Brigham and Women's Hospital, Boston, MA, 11Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 12Johns Hopkins Rheumatology, Baltimore, MD, 13Johns Hopkins University, Baltimore, MD, 14Johns Hopkins School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
  • Abstract Number: 0315 • ACR Convergence 2022

    The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab

    Evgeny Nasonov1, Eugen Feist2, Michael Luggen3, Sergey Yakushin4, Daria Bukhanova5, Alina Egorova6, Sergey Grishin6, Mikhail Samsonov5 and Josef Smolen7, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany, 3University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH, 4Ryazan State Medical University named after academician I.P. Pavlov, Ryazan, Russia, 5R-Pharm JSC, Moscow, Russia, 6R-Pharm, Moscow, Russia, 7Medical University of Vienna, Vienna, Austria

    Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…
  • Abstract Number: 0887 • ACR Convergence 2022

    Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database

    Byung Wook Song, Dong-Hyuk Moon, Aran Kim and Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea

    Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…
  • Abstract Number: 1728 • ACR Convergence 2022

    Increased Frequency of Highly Differentiated T Effector Memory Cells Re-expressing CD45RA (Temra) and Cytomegalovirus Seropositivity Are Associated with Persistent Disease Specifically Refractory to Anti-TNF Therapy in Rheumatoid Arthritis

    Su-Ann Yeoh, James Kimpton, Muhammad Shipa, Eleanor Hawkins, Arne Akbar and Michael Ehrenstein, University College London, London, United Kingdom

    Background/Purpose: Enrichment of highly differentiated T cells have been reported in rheumatoid arthritis (RA) patients compared to healthy individuals. The role of highly differentiated T…
  • Abstract Number: 0372 • ACR Convergence 2022

    Incidence and Risk of Overall Infections in Patients with Ankylosing Spondylitis Receiving Biologic Therapies: A Real-world Prospective Observational Study Using KOBIO Registry

    Kyung Min Ko1 and Su-Jin Moon2, 1International St. Mary's Hospital, Incheon, Republic of Korea, 2Catholic University of Korea, Seoul, Republic of Korea

    Background/Purpose: Infection is a perpetual concern in patients treated with biological therapy. However, long-term real-world data on infectious profile of AS patients are lacking The…
  • Abstract Number: 0934 • ACR Convergence 2022

    Impact of Tapering Targeted Therapy on Disease Activity Is Different Based on Concomitant Methotrexate Use in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

    Jun Won Park1, Min Jung Kim2, Hyoun-Ah Kim3, Jinhyun Kim4, Eun Bong Lee1 and Kichul Shin5, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 3Ajou University School of Medicine, Suwon, Republic of Korea, 4Chungnam National University Hospital, Jung-gu, Daejeon, South Korea, 5Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea

    Background/Purpose: The American College of Rheumatology and the European League Against Rheumatism recommend using methotrexate (MTX) with targeted therapy. Previous studies have shown that tapering…
  • Abstract Number: 1832 • ACR Convergence 2022

    Efficacy and Safety Similarity of Biosimilar Adalimumab-aqvh to Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Phase III Study

    Barbara Finck, Helen Tang, Kathy Jensen, Francesca Civoli and Suzanna Tatarewicz, Coherus BioSciences, Redwood City, CA

    Background/Purpose: This study aimed to demonstrate that there were no clinically meaningful differences between adalimumab-aqvh, a US Food and Drug Administration–approved biosimilar, and adalimumab in…
  • Abstract Number: 0414 • ACR Convergence 2022

    Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis with Intolerance to And/or Lack of Efficacy of Prior Biologic Therapy: A Subgroup Analysis

    Xenofon Baraliakos1, Fabiana Ganz2, Hideto Kameda3, Jessica Walsh4, Manish Jain5, Kristin D’Silva6, Peter Wung6, Xianwei Bu6, Jayne Stigler6 and Désirée van der Heijde7, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2AbbVie, Inc., Luzern, Switzerland, 3Toho University, Tokyo, Japan, 4University of Utah, Salt Lake City, UT, 5Great Lakes Clinical Trials, Chicago, IL, 6AbbVie, Inc., North Chicago, IL, 7Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands

    Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has been evaluated in the treatment of AS both in patients (pts) naïve to biologic DMARDs (bDMARDs)1…
  • Abstract Number: 0945 • ACR Convergence 2022

    Contraception Documentation Patterns for Adult Females with Juvenile Idiopathic Arthritis on Teratogenic Medications in the Rheumatology Informatics System for Effectiveness (RISE) Registry

    John Bridges1, Jing Li2, Melissa Mannion3, Gabriela Schmajuk4 and Jasvinder singh3, 1University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, 2University of California, San Francisco, San Francisco, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4UCSF / SFVA, San Francisco, CA

    Background/Purpose: Patients with juvenile idiopathic arthritis (JIA) have disease onset during childhood and often require anti-rheumatic medication through their reproductive years. Contraception use in reproductive-age…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology